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Introduction
One of the presentations of ovarian hyperstimulation
syndrome (OHSS) is an increase in ovarian size and the
presence of numerous luteal cysts. Hyperstimulation is
more severe when pregnancy occurs, as the developing
pregnancy produces the hormone human chorionic
gonadotropin (hCG), which stimulates the ovaries to
continue to grow [1,2]. If no pregnancy occurs, the
syndrome will typically resolve within 1 week. In the
setting of a maintained pregnancy, slow resolution of
symptoms of luteal cysts usually occurs over 1–2 months
and rarely persists until 5 months of gestation [3]. In
this report, we describe a case of bilateral megalocys-
tic ovaries in a patient with polycystic ovarian syn-
drome (PCOS) who became pregnant following in vitro
fertilization (IVF). The large ovarian cysts persisted
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Objective: Ovarian hyperstimulation syndrome (OHSS) is more severe when pregnancy occurs, as the developing
pregnancy produces human chorionic gonadotropin, which stimulates the ovary’s persistent growth. If no
pregnancy occurs, the syndrome will typically resolve within 1 week. In a maintained pregnancy, slow resolution
of symptoms usually occurs over 1–2 months.
Case Report: A 31-year-old woman, gravida 2, para 1, aborta 1, with polycystic ovary syndrome underwent
in vitro fertilization (IVF) with clomiphene citrate and follicle-stimulating hormone/gonadotropin releasing
hormone-antagonist stimulation. During transvaginal oocyte retrieval, enlarged bilateral ovaries were noted.
She had an episode of OHSS after IVF/embryo transfer, for which paracentesis was performed three times.
Pregnancy was achieved. Throughout antenatal examinations, bilateral ovaries were enlarged. She delivered
a healthy baby by cesarean section at term. However, 1 month after delivery, the bilateral ovary had not shrunk,
and levels of tumor markers CA125 and CA199 were 50.84 and 41.34 U/mL, respectively. At laparotomy for
suspected malignancy, both adnexae formed “kissing ovaries”, which were multinodulated with yellow serous
fluid. Specimens from wedge resection submitted for frozen section showed a benign ovarian cyst. The final
pathology report showed bilateral follicle cysts.
Conclusion: With the increasing use of gonadotropins in the management of infertility, ovarian enlargement
secondary to hyperstimulation is common. Generally, symptoms appear between the 6th and 13th weeks of
pregnancy and disappear thereafter. The hyperstimulated ovary often subsides after the first trimester. This
case is unusual as the megalocystic ovary persisted after delivery. To the best of our knowledge, we report
the first case of enlarged bilateral ovaries persisting 2 months after delivery. [Taiwanese J Obstet Gynecol 2006;
45(1):70–72]
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throughout the pregnancy and 2 months postpartum.
To the best of our knowledge, this is the first case of
enlarged bilateral ovaries that persisted 2 months after
delivery.
Case Report
A 31-year-old woman, gravida 2, para 1, aborta 1, with
PCOS underwent several attempts at ovulation induction
and intrauterine insemination. After these failed, she
underwent IVF with clomiphene citrate (CC)/
gonadotropin releasing hormone (GnRH)-antagonist
stimulation [4], receiving CC 100 mg daily for 5 days
(menstrual cycle days 3–7) and 150 IU recombinant
follicle-stimulating hormone (Gonal-F; Serono,
Singapore) at an interval of 2 days (days 4, 6, 8, and 10).
The GnRH-antagonist cetrorelix acetate 2.5 mg (Cetrotide;
Asta Medica, Frankfurt, Germany) was given on day 10
to prevent a premature luteinizing hormone surge. A high
serum estrogen level was noted on day 13 (7,993 pg/mL).
hCG 1,000 IU was injected on day 14. Transvaginal
ultrasound revealed 29 follicles with a diameter of more
than 12 mm. Transvaginal oocyte retrieval on day 16 was
uneventful, yielding 34 mature oocytes. The embryos were
transferred on day 18. The patient had severe OHSS 7 days
subsequent to oocyte retrieval, for which paracentesis was
performed three times, with an average of 1,500 mL
abdominal effusion drained each time. Pregnancy was
achieved. Throughout prenatal examinations, bilateral
ovaries were found to be enlarged, with the right ovary
measuring about 15 = 10 cm and the left 10 = 8 cm on
ultra-sonography. The patient delivered a healthy baby
via cesarean section at term, when enlarged bilateral
ovaries up to 20 cm in diameter were noted. No inter-
vention was made due to our expectation that the
hyperstimulated ovaries would shrink postpartum.
However, 2 months after delivery, the size of the bilateral
ovaries had not subsided, and concentrations of tumor
markers CA125 and CA199 were 50.84 and 41.34 U/mL,
respectively. Therefore, laparotomy was performed for
suspected malignancy. At laparotomy, both adnexae
were markedly enlarged, the right ovary measuring about
14 = 9 cm and the left about 14 = 7 cm, forming “kissing
ovaries” that stuck closely together and were mult-
inodulated with yellow serous fluid. There was minimal
ascites in the abdominal cavity. After wedge resection,
samples were sent for frozen section pathology, which
showed a benign ovarian cyst. The final pathology report
showed bilateral follicle cysts. The cytological evaluation
of the peritoneal fluid was negative for malignancy. The
postoperative course was uneventful, and the patient
was discharged home 3 days after surgery.
Discussion
OHSS is an iatrogenic complication of ovarian sti-
mulation occurring during the luteal phase or early
pregnancy. With the increasing use of gonadotropins
in the management of infertility, ovarian enlargement
secondary to hyperstimulation is common. Generally,
symptoms appear between the 6th and 13th weeks of
pregnancy and disappear thereafter. The hypersti-
mulated ovary often subsides after the first trimester
[5]. This case is unusual as the megalocystic ovary per-
sisted after delivery, with elevation of tumor markers.
To the best of our knowledge, this is the first re-
ported case of enlarged bilateral ovaries following
OHSS that persisted for 1 month after delivery. Ovarian
enlargement with multiple follicular and lutein cysts
persists for a longer period if pregnancy ensues. This is
probably because of continuous exposure of the ova-
ries to endogenous hCG [6]. However, plasma hCG
levels increase from the day of implantation to reach a
peak at about 60–70 days, then, beginning at about 10–
12 weeks, the levels of hCG in maternal plasma begin
to decline, a nadir being reached by about 20 weeks
that is maintained for the remainder of the pregnancy
[7]. Therefore, hyperstimulated ovaries often subside
when the hCG levels start to decline at 10–12 weeks and
reach a nadir at 20 weeks, as it has been reported that
hyperstimulated ovaries may persist to the 20th week
[5].
A variety of cystic ovarian conditions may develop
during pregnancy. Most of these conditions represent
exaggerated functional cysts, hyperreactio luteinalis
(HL). The recommended approach for a pregnant pa-
tient with the sonographic findings of bilateral multi-
locular ovarian cysts is primarily noninterventional
because the cysts in HL regress once pregnancy ends [8–
10]. HL is the second most common ovarian disorder of
pregnancy after luteoma of pregnancy and is charac-
terized by bilateral cystic enlargement of the ovaries
[11]. The ovaries may be moderately to massively en-
larged by multiple luteinized follicle cysts, secondary
to stimulation with hCG and gonadotropins [8]. In the
absence of a definitive tissue diagnosis, all patients with
enlarged cystic ovaries and a presumptive clinical diag-
nosis of pregnancy luteoma or HL should be carefully
followed postpartum to ensure complete regression.
The natural history of HL is postpartum regression [12].
Although uncommon, benign, low-malignant
potential, and malignant neoplastic disorders may also
first come to clinical attention during pregnancy. Few
studies have suggested that women treated with inferti-
lity drugs are at higher risk for ovarian cancer than the
general population [13,14]. As in this case, persistent
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enlarged bilateral ovaries and elevated tumor markers
raise suspicions of malignancy, leading to surgical
intervention. However, it is possible that the cyst will
resolve spontaneously without surgery.
In conclusion, patients who are pregnant after
gonadotropin therapy should be monitored for ovarian
enlargement for more than 2 months postpartum.
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